Bicycle Capital Expenditures vs Change In Cash Analysis

BCYC Stock

USD 21.09 0.23 1.10%

Bicycle Therapeutics financial indicator trend analysis is way more than just evaluating Bicycle Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Bicycle Therapeutics is a good investment. Please check the relationship between Bicycle Therapeutics Capital Expenditures and its Change In Cash accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bicycle Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

For information on how to trade Bicycle Stock refer to our How to Trade Bicycle Stock guide.

Capital Expenditures vs Change In Cash

Capital Expenditures vs Change In Cash Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Bicycle Therapeutics Capital Expenditures account and Change In Cash. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Bicycle Therapeutics' Capital Expenditures and Change In Cash is -0.22. Overlapping area represents the amount of variation of Capital Expenditures that can explain the historical movement of Change In Cash in the same time period over historical financial statements of Bicycle Therapeutics, assuming nothing else is changed. The correlation between historical values of Bicycle Therapeutics' Capital Expenditures and Change In Cash is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Expenditures of Bicycle Therapeutics are associated (or correlated) with its Change In Cash. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Change In Cash has no effect on the direction of Capital Expenditures i.e., Bicycle Therapeutics' Capital Expenditures and Change In Cash go up and down completely randomly.

Correlation Coefficient

-0.22

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Capital Expenditures

Capital Expenditures are funds used by Bicycle Therapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Bicycle Therapeutics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Change In Cash

Most indicators from Bicycle Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Bicycle Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bicycle Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

For information on how to trade Bicycle Stock refer to our How to Trade Bicycle Stock guide.At present, Bicycle Therapeutics' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Issuance Of Capital Stock is expected to grow to about 267.8 M, whereas Sales General And Administrative To Revenue is forecasted to decline to 1.89.

Bicycle Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Other Assets	Cash And Short Term Investments	Net Receivables	Capital Surpluse	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Property Plant Equipment	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Non Current Assets Total	Non Currrent Assets Other	Common Stock Shares Outstanding	Non Current Liabilities Total	Net Invested Capital	Property Plant And Equipment Gross
Total Assets		0.95	0.98	0.97	0.96	-0.97	0.86	1.0	0.93	1.0	0.84	0.86	0.99	0.79	1.0	0.97	0.96	0.86	0.87	-0.99	0.85	0.78	0.9	0.07	0.98	0.95
Other Current Liab	0.95		0.98	0.9	0.9	-0.98	0.89	0.94	0.99	0.94	0.91	0.86	0.96	0.78	0.94	0.95	0.97	0.87	0.82	-0.91	0.87	0.86	0.89	0.02	0.92	0.96
Total Current Liabilities	0.98	0.98		0.93	0.92	-0.99	0.92	0.97	0.98	0.97	0.86	0.84	0.99	0.77	0.97	0.96	0.99	0.86	0.86	-0.96	0.86	0.82	0.91	0.09	0.95	0.98
Total Stockholder Equity	0.97	0.9	0.93		0.99	-0.92	0.81	0.97	0.86	0.97	0.77	0.88	0.97	0.63	0.97	0.96	0.93	0.85	0.89	-0.98	0.84	0.74	0.88	-0.04	0.99	0.93
Net Tangible Assets	0.96	0.9	0.92	0.99		-0.9	0.75	0.96	0.86	0.96	0.81	0.92	0.96	0.67	0.96	0.97	0.91	0.87	0.89	-0.96	0.86	0.77	0.88	-0.12	1.0	0.92
Retained Earnings	-0.97	-0.98	-0.99	-0.92	-0.9		-0.94	-0.96	-0.98	-0.96	-0.86	-0.84	-0.98	-0.76	-0.96	-0.96	-0.98	-0.85	-0.84	0.95	-0.85	-0.8	-0.9	-0.09	-0.94	-0.96
Accounts Payable	0.86	0.89	0.92	0.81	0.75	-0.94		0.86	0.91	0.86	0.68	0.65	0.89	0.65	0.86	0.83	0.93	0.71	0.69	-0.87	0.71	0.67	0.77	0.26	0.8	0.9
Cash	1.0	0.94	0.97	0.97	0.96	-0.96	0.86		0.92	1.0	0.82	0.85	0.99	0.78	1.0	0.96	0.95	0.84	0.87	-0.99	0.83	0.76	0.89	0.08	0.98	0.95
Other Assets	0.93	0.99	0.98	0.86	0.86	-0.98	0.91	0.92		0.92	0.9	0.81	0.95	0.81	0.93	0.92	0.97	0.85	0.79	-0.89	0.86	0.87	0.87	0.09	0.89	0.96
Cash And Short Term Investments	1.0	0.94	0.97	0.97	0.96	-0.96	0.86	1.0	0.92		0.82	0.85	0.99	0.78	1.0	0.96	0.95	0.84	0.87	-0.99	0.83	0.76	0.89	0.08	0.98	0.95
Net Receivables	0.84	0.91	0.86	0.77	0.81	-0.86	0.68	0.82	0.9	0.82		0.83	0.84	0.85	0.83	0.86	0.83	0.87	0.83	-0.78	0.88	0.89	0.9	-0.02	0.82	0.82
Capital Surpluse	0.86	0.86	0.84	0.88	0.92	-0.84	0.65	0.85	0.81	0.85	0.83		0.89	0.59	0.86	0.95	0.8	0.75	0.74	-0.81	0.74	0.68	0.75	-0.42	0.91	0.79
Other Stockholder Equity	0.99	0.96	0.99	0.97	0.96	-0.98	0.89	0.99	0.95	0.99	0.84	0.89		0.73	0.99	0.99	0.97	0.86	0.87	-0.98	0.85	0.78	0.89	0.01	0.98	0.96
Total Liab	0.79	0.78	0.77	0.63	0.67	-0.76	0.65	0.78	0.81	0.78	0.85	0.59	0.73		0.79	0.7	0.74	0.74	0.72	-0.74	0.75	0.76	0.79	0.3	0.7	0.73
Total Current Assets	1.0	0.94	0.97	0.97	0.96	-0.96	0.86	1.0	0.93	1.0	0.83	0.86	0.99	0.79		0.97	0.95	0.84	0.87	-0.99	0.84	0.77	0.89	0.07	0.98	0.95
Common Stock	0.97	0.95	0.96	0.96	0.97	-0.96	0.83	0.96	0.92	0.96	0.86	0.95	0.99	0.7	0.97		0.93	0.83	0.84	-0.94	0.82	0.75	0.86	-0.14	0.98	0.92
Property Plant Equipment	0.96	0.97	0.99	0.93	0.91	-0.98	0.93	0.95	0.97	0.95	0.83	0.8	0.97	0.74	0.95	0.93		0.9	0.85	-0.95	0.9	0.86	0.9	0.12	0.93	1.0
Property Plant And Equipment Net	0.86	0.87	0.86	0.85	0.87	-0.85	0.71	0.84	0.85	0.84	0.87	0.75	0.86	0.74	0.84	0.83	0.9		0.93	-0.85	1.0	0.96	0.94	0.08	0.86	0.92
Current Deferred Revenue	0.87	0.82	0.86	0.89	0.89	-0.84	0.69	0.87	0.79	0.87	0.83	0.74	0.87	0.72	0.87	0.84	0.85	0.93		-0.89	0.91	0.81	0.98	0.15	0.89	0.87
Net Debt	-0.99	-0.91	-0.96	-0.98	-0.96	0.95	-0.87	-0.99	-0.89	-0.99	-0.78	-0.81	-0.98	-0.74	-0.99	-0.94	-0.95	-0.85	-0.89		-0.83	-0.75	-0.9	-0.14	-0.97	-0.94
Non Current Assets Total	0.85	0.87	0.86	0.84	0.86	-0.85	0.71	0.83	0.86	0.83	0.88	0.74	0.85	0.75	0.84	0.82	0.9	1.0	0.91	-0.83		0.97	0.94	0.09	0.85	0.92
Non Currrent Assets Other	0.78	0.86	0.82	0.74	0.77	-0.8	0.67	0.76	0.87	0.76	0.89	0.68	0.78	0.76	0.77	0.75	0.86	0.96	0.81	-0.75	0.97		0.87	0.1	0.77	0.88
Common Stock Shares Outstanding	0.9	0.89	0.91	0.88	0.88	-0.9	0.77	0.89	0.87	0.89	0.9	0.75	0.89	0.79	0.89	0.86	0.9	0.94	0.98	-0.9	0.94	0.87		0.2	0.89	0.91
Non Current Liabilities Total	0.07	0.02	0.09	-0.04	-0.12	-0.09	0.26	0.08	0.09	0.08	-0.02	-0.42	0.01	0.3	0.07	-0.14	0.12	0.08	0.15	-0.14	0.09	0.1	0.2		-0.07	0.12
Net Invested Capital	0.98	0.92	0.95	0.99	1.0	-0.94	0.8	0.98	0.89	0.98	0.82	0.91	0.98	0.7	0.98	0.98	0.93	0.86	0.89	-0.97	0.85	0.77	0.89	-0.07		0.93
Property Plant And Equipment Gross	0.95	0.96	0.98	0.93	0.92	-0.96	0.9	0.95	0.96	0.95	0.82	0.79	0.96	0.73	0.95	0.92	1.0	0.92	0.87	-0.94	0.92	0.88	0.91	0.12	0.93

Click cells to compare fundamentals

Bicycle Therapeutics Account Relationship Matchups

Bicycle Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	110.2M	161.2M	479.8M	410.6M	595.3M	625.1M
Other Current Liab	5.5M	10.8M	11.9M	23.3M	26.6M	28.0M
Total Current Liabilities	8.8M	23.1M	36.2M	53.3M	69.5M	73.0M
Total Stockholder Equity	93.2M	95.5M	346.3M	270.8M	370.9M	389.5M
Other Liab	6.9M	27.6M	55.3M	45.3M	52.1M	26.8M
Net Tangible Assets	93.2M	95.5M	346.3M	270.8M	311.4M	327.0M
Retained Earnings	(100.6M)	(151.6M)	(218.4M)	(331.1M)	(511.8M)	(486.2M)
Accounts Payable	1.9M	1.4M	2.7M	6.5M	13.1M	13.7M
Cash	92.1M	136.0M	438.7M	339.2M	526.4M	552.7M
Other Assets	1.7M	3.1M	3.4M	8.5M	9.7M	10.2M
Cash And Short Term Investments	92.1M	136.0M	438.7M	339.2M	526.4M	552.7M
Net Receivables	7.1M	14.6M	11.9M	21.2M	24.0M	13.0M
Common Stock Total Equity	5K	10K	227K	266K	305.9K	321.2K
Other Current Assets	4.9M	5.1M	8.0M	9.0M	11.4M	12.0M
Other Stockholder Equity	195.1M	249.9M	567.6M	601.1M	883.4M	927.6M
Total Liab	17.0M	65.7M	133.5M	139.8M	224.4M	117.8M
Total Current Assets	104.1M	155.7M	458.6M	369.4M	561.9M	590.0M
Accumulated Other Comprehensive Income	(1.5M)	(3.2M)	(3.4M)	387K	(1.3M)	(1.4M)
Short Term Debt	640K	844K	2.4M	3.1M	4.9M	5.1M
Common Stock	227K	266K	384K	387K	550K	577.5K
Property Plant Equipment	4.3M	3.6M	17.8M	32.8M	37.7M	39.6M
Property Plant And Equipment Net	4.3M	3.6M	17.8M	32.8M	27.7M	14.0M
Current Deferred Revenue	728K	10.1M	19.3M	20.4M	25.0M	12.5M
Net Debt	(90.2M)	(120.2M)	(394.3M)	(294.8M)	(481.5M)	(457.4M)
Non Current Assets Total	6.0M	5.4M	21.2M	41.2M	33.5M	18.0M
Non Currrent Assets Other	1.7M	1.8M	3.4M	8.5M	5.8M	4.0M
Common Stock Shares Outstanding	11.0M	19.1M	25.1M	29.7M	35.6M	23.1M
Liabilities And Stockholders Equity	110.2M	161.2M	479.8M	410.6M	595.3M	300.6M
Non Current Liabilities Total	8.2M	42.6M	97.3M	86.5M	154.9M	101.1M
Net Invested Capital	93.2M	110.0M	376.1M	301.1M	401.6M	421.7M
Property Plant And Equipment Gross	4.3M	3.6M	22.6M	40.6M	41.1M	43.1M
Non Current Liabilities Other	2.0M	2.6M	3.3M	3.8M	4.6M	2.8M
Net Working Capital	95.3M	132.6M	422.3M	316.0M	492.3M	249.6M
Capital Stock	227K	266K	384K	387K	550K	334.4K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

When determining whether Bicycle Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bicycle Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bicycle Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bicycle Therapeutics Stock:

How To Invest In Bicycle

Details

Is Bicycle Stock a good investment?

Details

What is Bicycle Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bicycle Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing.

For information on how to trade Bicycle Stock refer to our How to Trade Bicycle Stock guide.

You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bicycle Therapeutics. If investors know Bicycle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bicycle Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(3.28)

Revenue Per Share

0.716

Quarterly Revenue Growth

(0.50)

Return On Assets

(0.15)

Return On Equity

(0.27)

The market value of Bicycle Therapeutics is measured differently than its book value, which is the value of Bicycle that is recorded on the company's balance sheet. Investors also form their own opinion of Bicycle Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Bicycle Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bicycle Therapeutics' market value can be influenced by many factors that don't directly affect Bicycle Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Bicycle Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bicycle Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bicycle Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Bicycle Capital Expenditures vs Change In Cash Analysis

Capital Expenditures vs Change In Cash

Capital Expenditures vs Change In Cash Correlation Analysis

Correlation Coefficient

Capital Expenditures

Change In Cash

Bicycle Therapeutics fundamental ratios Correlations

Bicycle Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Bicycle Therapeutics fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Net Tangible Assets
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash

Net Debt	- 0.99	Total Current Assets
Net Debt	- 0.99	Cash And Short Term Investments
Net Debt	- 0.99	Cash
Retained Earnings	- 0.99	Total Current Liabilities
Net Debt	- 0.99	Total Assets
Net Debt	- 0.98	Other Stockholder Equity